BioInvent International AB announces that it has further extended the research term under its cancer immunotherapy research collaboration and License Agreement with Pfizer Inc. until the end of 2020. In December 2016, the companies entered into the agreement for the development and commercialization of antibodies targeting tumor-associated myeloid cells discovered using BioInvent’s proprietary F.I.R.S.TTM drug […]